Table 5.
Univariate and multivariate analysisa for TTR by Cox Proportional Hazards Regression in stage II and stage III colon cancer after PSM.
| Characteristic | Unadjusted analysis | Adjusted analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Stage II | Stage III | Stage II | Stage III | |||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Location | ||||||||
| Right | 3.20 (1.28–4.48) | < 0.01a | 1.09 (0.69–1.72) | 0.72 | 4.26 (1.61–11.28) | < 0.01 | ||
| Left | 1 | 1 | 1 | |||||
| Age (for every 1 additional year in age) | 0.99 (0.96–1.02) | 0.42 | 1.01 (0.99–1.02) | 0.55 | ||||
| Gender | ||||||||
| Male | 0.74 (0.33–1.64) | 0.45 | 0.997 (0.63–1.57) | 0.99 | ||||
| Female | 1 | 1 | 1 | |||||
| BMI (for every 1 additional in BMI) | 0.90 (0.81–1.00) | 0.049a | 0.93 (0.87–0.99) | 0.02a | 0.87 (0.77–0.98) | 0.02 | 0.91 (0.85–0.97) | <0.01 |
| Patient origin | ||||||||
| Elective operation | 1 | 1 | 1 | 1 | ||||
| Emergency operation | 2.57 (0.88–7.50) | 0.08a | 1.84 (1.01–3.35) | 0.04a | 1.12 (0.34–3.70) | 0.85 | 1.37 (0.72–2.61) | 0.34 |
| Operation method | ||||||||
| Open surgery | 1.75 (0.80–3.83) | 0.16a | 1.45 (0.92–2.29) | 0.11a | 0.95 (0.38–2.38) | 0.91 | 1.21 (0.73–20.1) | 0.47 |
| Minimal invasive surgery | 1 | 1 | 1 | |||||
| CEA (for every 1 additional in CEA) | 0.997 (0.97–1.03) | 0.78 | 1.00 (0.997–1.01) | 0.37 | ||||
| Lymphovascular invasion (LVI) | ||||||||
| LVI (−) | 1 | 1 | 1 | |||||
| LVI(+) | 1.91 (0.88–4.19) | 0.11a | 1.21 (0.72–2.03) | 0.48 | 1.83 (0.78–4.31) | 0.17 | ||
| Perineural invasion (PNI) | ||||||||
| PNI (−) | 1 | 1 | 1 | 1 | ||||
| PNI (+) | 1.71 (0.78–3.78) | 0.18a | 2.01 (1.22–3.31) | < 0.01a | 1.60 (0.70–3.65) | 0.27 | 1.79 (1.04–3.06) | 0.04 |
| Surgical margin | ||||||||
| R0 resection | 1 | 1 | 1 | |||||
| R1 resection | 14.80 (4.87–45.01) | < 0.01a | 1.01 (0.41–2.49) | 0.99 | 25.06 (5.59–112.46) | < 0.01 | ||
| Tumor grade | ||||||||
| Grade 1–2 | 1 | 1 | ||||||
| Grade 3–4 | 0.44 (0.06–3.24) | 0.42 | 0.99 (0.36–2.71) | 0.98 | ||||
| T stage | ||||||||
| T1 | 1 | < 0.01a | 1 | <0.01 | ||||
| T2 | 0.64 (0.04–10.30) | 0.84 (0.05–13.52) | ||||||
| T3 | 1 | 3.43 (0.47–24.99) | 1 | 2.85 (0.38–21.332) | ||||
| T4 | 3.79 (1.70–8.44) | < 0.01a | 7.42 (1.01–54.32) | 2.04 (0.81–5.14) | 0.13 | 5.82 (0.77–44.28) | ||
| N stage | ||||||||
| N0 | ||||||||
| N1 | 1 | 1 | ||||||
| N2 | 2.01 (1.27–3.17) | < 0.01a | 1.74 (1.09–2.77) | 0.02 | ||||
| Tumor size (for every additional 1 cm) | 0.94 (0.79–1.12) | 0.49 | 1.07 (0.97–1.18) | 0.195a | 1.01 (0.90–1.13) | 0.83 | ||
| Lymph node harvested (for every additional 1 lymph node harvested) | 0.99 (0.96–1.03) | 0.74 | 0.997 (0.98–1.02) | 0.72 | ||||
| Adjuvant chemotherapy | ||||||||
| No | 1 | 1 | 1 | |||||
| Yes | 2.37 (0.99–5.68) | 0.053a | 1.05 (0.59–1.84) | 0.88 | 2.69 (1.06–6.83) | 0.04 | ||
Significant values are in bold.
BMI Body mass index, CEA carcinoembryonic antigen.
aOnly variables with p<0.2 in univariate analysis were included to multivariate analysis.